Effects of behavioral sleep extension on Alzheimers disease relevant blood biomarkers and cognitive performance

行为睡眠延长对阿尔茨海默病相关血液生物标志物和认知能力的影响

• 批准号: 10288146
• 负责人: Kelly Glazer Baron
• 金额: $ 33.78万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-27 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10288146
• 关键词: Acute; Adolescent; Adult; Age; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Alzheimer’s disease biomarker; Ambulatory Blood Pressure Monitoring; Amino Acids; Area; Behavioral; Biochemical Pathway; Biological; Biological Assay; Biological Markers; Blood; Blood Pressure; Blood specimen; Body mass index; Brain; Cardiometabolic Disease; Clinical Trials; Cognition; Cognitive; Consensus; Control Groups; Data; Dementia; Development; Diagnostic; Diet; Disease; Drowsiness; Elderly; Epidemiology; Future; Goals; Grant; Health; Health education; Hour; Hypertension; Impact evaluation; Impaired cognition; Individual; Inflammation; Intervention; Laboratories; Lead; Learning; Link; Literature; Maintenance; Measures; Mediator of activation protein; Metabolic; National Health Interview Survey; Neurodegenerative Disorders; Outcome; Outcome Measure; Parents; Patient Self-Report; Performance; Physical activity; Physiological; Population; Populations at Risk; Quality of life; Randomized; Randomized Controlled Trials; Recommendation; Reporting; Research; Risk; Risk Factors; Sleep; Sleep Disorders; Testing; Time; Vascular Dementia; Visuospatial; acylcarnitine; base; behavioral phenotyping; biomarker identification; biomarker panel; biomarker performance; cardiometabolic risk; cardiometabolism; cognitive change; cognitive performance; cognitive testing; comparison intervention; dementia risk; design; disorder risk; epidemiology study; experimental study; follow-up; glycemic control; improved; improvement on sleep; metabolomics; middle age; mild cognitive impairment; modifiable risk; novel; pre-clinical; predictive marker; prehypertension; primary outcome; processing speed; psychologic; public health relevance; response; response biomarker; secondary outcome; small molecule; tool; vigilance; young adult

PROJECT SUMMARY/ABSTRACT Decades of experimental and epidemiologic research link short sleep duration to adverse cardiometabolic health. Furthermore, emerging research points to direct biological mechanisms linking short sleep duration to cognitive decline and Alzheimer’s disease. Despite decades documenting the deleterious effects of short sleep duration, few studies have sought to improve risk or modify Alzheimer’s disease trajectories by extending sleep. Sleep extension interventions hold promise to improve cardiometabolic disease (CMD) risk, cognition and quality of life. To date, several small studies have demonstrated short term improvements in sleep and CMD risk such as blood pressure and glycemic control. However, existing studies in adults have not addressed whether sleep extension interventions impact cognitive performance and biomarkers of Alzheimer’s Disease risk. The goal of this application is to extend the aims of our parent study to include an examination of the impact of our randomized behavioral sleep extension intervention on Alzheimer’s related biomarkers (blood metabolomics) and cognitive performance measures. In our parent study, we are conducting a randomized controlled trial to test our behavioral sleep extension intervention compared to a health education control group on sleep and CMD risk among adults with prehypertension/stage I hypertension. The 12-month study includes an intervention period (weeks 1-8, weekly intervention), maintenance period (months 2-6, monthly intervention) and follow-up period (no intervention). The primary outcome for the parent study is sleep duration and the main secondary outcome is 24-h ambulatory blood pressure monitoring, which allows us to evaluate both daytime and nighttime blood pressures. The design of this parent study will allow us to examine the acute (8 week) and sustained (12 month) changes in sleep duration, BP and important psychological, behavioral and physiological mediators including self-reported sleepiness, BMI, diet, physical activity, glycemic control and inflammation. The receipt of this Alzheimer’s disease supplement will allow us to extend the scope of our parent study to examine the effects of our sleep extension intervention on blood biomarkers and cognitive performance. Successful completion of this study will provide critical information about the impact of behavioral sleep extension on important measures of health and quality of life needed to incorporate sleep extension into CMD, and potentially Alzheimer’s disease risk interventions. Completion of this supplement will identify potential biochemical pathways and behavioral phenotypes that respond to sleep extension. Identification of these biological and behavioral markers of response to sleep extension has the potential to lead to identification of biomarkers and novel targets to reduce Alzheimer’s Disease risk.

项目摘要/摘要 实验和流行病学研究数十年 健康。此外，新兴的研究指向将短睡眠时间连接到的生物学机制直接 认知能力下降和阿尔茨海默氏病。尽管记录了短睡眠的有害影响 持续时间，很少有人认为通过扩展来改善风险或改变阿尔茨海默氏病轨迹 睡觉。睡眠延长干预措施有望改善心脏代谢疾病（CMD）风险，认知 和生活质量。迄今为止，几项小型研究表明睡眠的短期改善和 CMD风险，例如血压和血糖控制。但是，在成年人中的现有研究尚未解决 睡眠延长干预措施是否影响认知表现和阿尔茨海默氏病的生物标志物 风险。该应用的目的是扩展我们的父母研究的目标，包括检查 我们随机行为睡眠延长干预对阿尔茨海默氏症相关的影响 生物标志物（血液代谢组学）和认知性能指标。在我们的父母研究中，我们是 与A相比，进行随机对照试验以测试我们的行为睡眠扩展干预措施 具有预期前/I期成年人的睡眠和CMD风险的健康教育控制小组 高血压。这项为期12个月的研究包括干预期（第1-8周，每周干预）， 维护期（2-6个月，每月干预）和随访期（无干预）。主要 父母研究的结果是睡眠持续时间，主要次要结果是24小时的卧床血液 压力监测，这使我们能够评估白天和夜间血压。设计 这项父母研究将使我们能够检查急性（8周）并持续（12个月）的睡眠变化 持续时间，BP以及重要的心理，行为和身体介体，包括自我报告 嗜睡，BMI，饮食，体育活动，血糖控制和注射。这个阿尔茨海默氏症的收到 疾病补充剂将使我们能够扩展父母研究的范围，以检查我们的影响 对血液生物标志物和认知表现的睡眠延长干预。成功完成 这项研究将提供有关行为睡眠扩展对重要的影响的关键信息 将睡眠延长纳入CMD所需的健康和生活质量的措施，并有可能 阿尔茨海默氏病风险干预。该补充剂的完成将确定潜在的生化 响应睡眠延伸的途径和行为表型。这些生物学和 对睡眠延长反应的行为标志物有可能导致生物标志物的识别和 降低阿尔茨海默氏病风险的新颖目标。